Voyager Therapeutics, Inc. Common Stock
Symbol: VYGR (NASDAQ)
Company Description:
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
- Today's Open: $4.5
- Today's High: $4.53
- Today's Low: $4.23
- Today's Volume: 915.46K
- Yesterday Close: $4.485
- Yesterday High: $4.56
- Yesterday Low: $4.3213
- Yesterday Volume: 656.68K
- Last Min Volume: 0
- Last Min High: $4.292
- Last Min Low: $4.291
- Last Min VWAP: $0
- Name: Voyager Therapeutics, Inc. Common Stock
- Website: https://www.voyagertherapeutics.com
- Listed Date: 2015-11-11
- Location: LEXINGTON, MA
- Market Status: Active
- CIK Number: 0001640266
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $236.85M
- Round Lot: 100
- Outstanding Shares: 55.47M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-09-02 | 8-K | View |
2025-08-20 | 4 | View |
2025-08-18 | 144 | View |
2025-08-14 | SCHEDULE 13G/A | View |
2025-08-06 | 10-Q | View |
2025-08-06 | 8-K | View |
2025-06-09 | S-8 | View |
2025-06-05 | 8-K | View |
2025-06-04 | 4 | View |
2025-06-04 | 4 | View |
2025-06-04 | 4 | View |
2025-06-04 | 4 | View |
2025-06-04 | 4 | View |
2025-06-04 | 4 | View |
2025-06-04 | 4 | View |
2025-06-04 | 4 | View |
2025-06-04 | 4 | View |
2025-05-15 | SCHEDULE 13G/A | View |
2025-05-06 | 10-Q | View |
2025-05-06 | 8-K | View |